JO3672B1 - أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). - Google Patents

أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Info

Publication number
JO3672B1
JO3672B1 JOP/2009/0481A JOP20090481A JO3672B1 JO 3672 B1 JO3672 B1 JO 3672B1 JO P20090481 A JOP20090481 A JO P20090481A JO 3672 B1 JO3672 B1 JO 3672B1
Authority
JO
Jordan
Prior art keywords
pcsk9
high affinity
human antibodies
little
affinity human
Prior art date
Application number
JOP/2009/0481A
Other languages
English (en)
Inventor
Macdonald Douglas
W Sleeman Mark
T Huang Tammy
H Martin Joel
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41668268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3672(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3672B1 publication Critical patent/JO3672B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)

Abstract

الجسم المضاد البشري او الجزء المرتبط بمولد الضد للجسم المضاد البشري الذي يرتبط تحديدا او يثبط انزيم hPCSK9يتميز بالقدرة على تخفيض مستوى كوليسترول الليبويروتين منخفض الكثافة بنسبة 40-80%, لفترة لا تقل عن 24 او60او90 يوما يوما حسب مستوى ما قبل الجرعة مع تخفيض تأثير ضئيل او لا يذكر على مستوى كوليسترول الليبوبروتين عالي الكثافة و/او تاثير ضئيل او لا يذكر على وظائف الكبد, على النحو الذي يحدده قياسات انزيم تحفيز الالينين وانزيم تحفيز اسبارتيك.
JOP/2009/0481A 2008-12-15 2009-12-14 أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). JO3672B1 (ar)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12248208P 2008-12-15 2008-12-15
US21056609P 2009-03-18 2009-03-18
US16875309P 2009-04-13 2009-04-13
US21813609P 2009-06-18 2009-06-18
US24913509P 2009-10-06 2009-10-06
US26177609P 2009-11-17 2009-11-17

Publications (1)

Publication Number Publication Date
JO3672B1 true JO3672B1 (ar) 2020-08-27

Family

ID=41668268

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0481A JO3672B1 (ar) 2008-12-15 2009-12-14 أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Country Status (46)

Country Link
US (9) US8062640B2 (ar)
EP (3) EP2358756B2 (ar)
JP (2) JP5318965B2 (ar)
KR (2) KR101504494B1 (ar)
CN (2) CN102245641B (ar)
AR (1) AR077724A1 (ar)
AU (1) AU2009333326B9 (ar)
BR (1) BRPI0922885B1 (ar)
CA (1) CA2747123C (ar)
CO (1) CO6571847A2 (ar)
CR (1) CR20110296A (ar)
CY (2) CY1118896T1 (ar)
DK (2) DK3156422T3 (ar)
DO (1) DOP2011000184A (ar)
EC (1) ECSP11011134A (ar)
ES (2) ES2898661T3 (ar)
FI (2) FI2358756T4 (ar)
FR (1) FR17C1022I2 (ar)
HN (1) HN2011001659A (ar)
HR (2) HRP20211688T1 (ar)
HU (3) HUE056244T2 (ar)
IL (2) IL213050A (ar)
JO (1) JO3672B1 (ar)
LT (3) LT3156422T (ar)
LU (1) LUC00024I2 (ar)
ME (2) ME01327B (ar)
MX (2) MX2011006197A (ar)
MY (1) MY203040A (ar)
NI (1) NI201100111A (ar)
NL (1) NL300879I2 (ar)
NO (1) NO2017029I2 (ar)
NZ (2) NZ601923A (ar)
PA (1) PA8854201A1 (ar)
PE (1) PE20120014A1 (ar)
PL (2) PL2358756T5 (ar)
PT (2) PT3156422T (ar)
RS (2) RS55771B2 (ar)
RU (2) RU2697773C2 (ar)
SI (2) SI2358756T2 (ar)
SM (1) SMT201700183T1 (ar)
TN (1) TN2011000300A1 (ar)
TW (1) TWI465249B (ar)
UA (1) UA105650C2 (ar)
UY (1) UY32329A (ar)
WO (1) WO2010077854A1 (ar)
ZA (1) ZA201103762B (ar)

Families Citing this family (316)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) * 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
AU2010313324A1 (en) * 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
NZ602220A (en) * 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
ES2667100T3 (es) * 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CN103261230A (zh) * 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
CA2825778A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
EP2481758A1 (en) 2011-01-28 2012-08-01 Sanofi Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
US8337530B2 (en) 2011-03-09 2012-12-25 Zimmer Spine, Inc. Polyaxial pedicle screw with increased angulation
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2013008185A1 (en) * 2011-07-14 2013-01-17 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
ITPC20110013U1 (it) 2011-10-07 2013-04-08 Giovanni Merli Struttura di protezione superiore veicoli.
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
ES2886123T3 (es) * 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
WO2014107739A1 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
AU2014235430A1 (en) * 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
EP2810955A1 (en) 2013-06-07 2014-12-10 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
ES2901400T3 (es) * 2013-06-07 2022-03-22 Regeneron Pharma Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX373298B (es) 2013-10-11 2020-05-20 Sanofi Biotechnology Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
ES2864350T3 (es) * 2013-11-12 2021-10-13 Regeneron Pharma Pautas posológicas para uso con inhibidores de PCSK9
US10428157B2 (en) * 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3572425A1 (en) * 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
EA201691320A1 (ru) 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
WO2015200438A1 (en) * 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
DE202015009006U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP4328245A3 (en) 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015289617B2 (en) * 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
JP2017523980A (ja) 2014-08-06 2017-08-24 ライナット ニューロサイエンス コーポレイション Ｌｄｌ−コレステロールを低下させるための方法
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
US10799630B2 (en) * 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CN105461809B (zh) * 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3271405A1 (en) 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
ES3063952T3 (en) 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
CN106084058B (zh) * 2015-07-15 2019-08-27 北京天广实生物技术股份有限公司 抗人pcsk9单克隆抗体
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
EA201890519A1 (ru) * 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN107406511B (zh) * 2015-12-31 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
IL260931B2 (en) * 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2017163049A1 (en) 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
CN107266575B (zh) * 2016-04-07 2021-12-24 天士力生物医药股份有限公司 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018054240A1 (en) * 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pcsk9 antibodies
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
EP3532127B1 (en) 2016-10-25 2026-04-08 Amgen Inc. On-body injector
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JOP20190112A1 (ar) 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
CN106749670B (zh) * 2017-01-22 2018-06-12 北京东方百泰生物科技有限公司 抗pcsk9单克隆抗体
CN108424457B (zh) * 2017-02-13 2021-06-01 成都金洛克锶生物技术有限公司 针对pcsk9抗体与检测试剂盒的制备及其用途
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
US9989519B1 (en) * 2017-05-04 2018-06-05 Clayton Pharmaceuticals, LLC Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD)
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
TW201904608A (zh) * 2017-06-09 2019-02-01 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CA3085177A1 (en) 2018-01-31 2019-08-08 Regeneron Pharamaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
WO2019152599A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US11957745B2 (en) 2018-02-22 2024-04-16 Vanderbilt University Human Japanese Encephalitis Virus antibodies and methods of use therefor
AU2019227531B2 (en) 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
IL277127B2 (en) 2018-03-06 2025-11-01 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
FI3817770T3 (fi) 2018-07-02 2026-07-06 Amgen Inc Antigeeniä sitova anti-steap1-proteiini
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020047067A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN110872353B (zh) * 2018-09-03 2021-05-04 深圳华大基因科技有限公司 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
CN111110841A (zh) * 2018-10-31 2020-05-08 上海君实生物医药科技股份有限公司 含有抗pcsk9抗体的稳定制剂
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
JP2022517720A (ja) 2019-01-16 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ジスルフィド結合を特徴付けるための方法
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
EP3958934B1 (en) 2019-04-24 2025-04-09 Amgen Inc. Syringe sterilization verification assemblies and methods
JP7541534B2 (ja) 2019-05-13 2024-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
EP3969620B1 (en) 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021058597A1 (en) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject is at risk of developing arterial plaques
KR20260058863A (ko) 2019-09-24 2026-04-29 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
JP2023506732A (ja) 2019-12-10 2023-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
JP7765457B2 (ja) * 2020-08-06 2025-11-06 ステレクシス セラピューティクス，エルエルシー Ｉｌ－８抗体及びその使用方法
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
TW202246325A (zh) 2021-03-03 2022-12-01 美商再生元醫藥公司 用於定量及修飾蛋白質黏度之系統及方法
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
AU2022307659A1 (en) 2021-07-05 2024-01-25 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
EP4413364A2 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
JP2026514305A (ja) 2023-05-01 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品
WO2024240848A1 (en) * 2023-05-23 2024-11-28 Jlp Health Gmbh Ldlr derived polypeptides for anti-viral uses
EP4467563A1 (en) * 2023-05-23 2024-11-27 JLP Health GmbH Ldlr derived polypeptides for anti-viral uses
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
EP4780828A2 (en) 2023-09-18 2026-07-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN122138969A (zh) 2023-10-18 2026-06-02 瑞泽恩制药公司 从过程中上游细胞培养物材料中快速纯化单克隆抗体
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025144700A1 (en) 2023-12-27 2025-07-03 Absci Corporation Nanobody library screening using bacterial surface display
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
TW202600593A (zh) 2024-02-16 2026-01-01 美商再生元醫藥公司 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same
WO2026112457A2 (en) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof
WO2026136650A1 (en) 2024-12-20 2026-06-25 Regeneron Pharmaceuticals, Inc. Fixed seed train schedule for improved protein production

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
AU687763B2 (en) 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US6086874A (en) 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
US6261560B1 (en) 1995-02-13 2001-07-17 Chugai Seiyaku Kabushiki Kaisha Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
JP2000509018A (ja) 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
AU2484399A (en) 1998-01-30 1999-08-16 Scios Inc. Controlled release delivery of peptide or protein
ATE383875T1 (de) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
AU9084601A (en) 2000-09-08 2002-03-22 Massachusetts Inst Technology G-csf analog compositions and methods
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
CA2555688C (en) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US20110313024A1 (en) 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
KR20080071192A (ko) 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
ES2366973T3 (es) 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimiento para modular la expresión génica.
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008057457A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008133647A2 (en) * 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
EA200900741A1 (ru) 2006-11-27 2010-04-30 Айзис Фармасьютикалз, Инк. Способы лечения гиперхолестеринемии
CN101589143A (zh) 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP5100101B2 (ja) 2006-12-12 2012-12-19 キヤノン株式会社 画像形成装置
AR066042A1 (es) 2007-04-13 2009-07-22 Novartis Ag Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CN101687927B (zh) 2007-05-15 2013-10-30 霍夫曼-拉罗奇有限公司 针对g蛋白偶联的受体（gpcr）的抗体
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20100286021A1 (en) 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
CN102232088A (zh) * 2007-10-26 2011-11-02 先灵公司 用于治疗脂类和胆固醇疾病的抗pcsk9及方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
PE20110302A1 (es) 2008-09-19 2011-05-21 Hoffmann La Roche Formulacion farmaceutica de un anticuerpo contra p-selectina
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20100216667A1 (en) 2008-12-17 2010-08-26 Meyer Brian K Method for determining compatibility of an active pharmaceutical ingredient with materials
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
MX2011013722A (es) 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
WO2011039578A1 (en) 2009-10-02 2011-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
PL3721904T3 (pl) 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
DE102010024698A1 (de) 2010-06-23 2011-12-29 Eads Deutschland Gmbh Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
US10023657B2 (en) * 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) * 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
CA2746171C (en) 2011-07-13 2018-11-06 William Jani Retrievable stimulation frac (rsf) plug
WO2013008185A1 (en) 2011-07-14 2013-01-17 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
JP5859148B2 (ja) 2012-03-08 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａβ抗体製剤
HK1207403A1 (en) 2012-04-19 2016-01-29 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
RU2538801C2 (ru) 2013-02-07 2015-01-10 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
TW201534324A (zh) * 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
MX373298B (es) 2013-10-11 2020-05-20 Sanofi Biotechnology Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) * 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) * 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
EA201691320A1 (ru) 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
US20150283236A1 (en) 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
CN114558129A (zh) 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015289617B2 (en) 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
TW201904608A (zh) 2017-06-09 2019-02-01 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
IL277127B2 (en) 2018-03-06 2025-11-01 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
DE102023206495B3 (de) 2023-07-07 2024-11-21 Volkswagen Aktiengesellschaft Integrierter Schaltkreis, Anordnung sowie Verfahren zum Einkoppeln von optischen Signalen in einen integrierten Schaltkreis

Also Published As

Publication number Publication date
TWI465249B (zh) 2014-12-21
NL300879I2 (nl) 2017-11-02
SI2358756T2 (sl) 2023-09-29
ES2613489T5 (es) 2024-01-25
RS55771B2 (sr) 2023-11-30
IL230771A0 (en) 2014-03-31
ME02760B (me) 2018-01-20
CA2747123C (en) 2018-01-09
HUE032681T2 (en) 2017-10-30
ME01327B (me) 2017-07-31
CR20110296A (es) 2011-07-14
EP2358756B2 (en) 2023-07-26
PL2358756T5 (pl) 2023-11-06
NZ593155A (en) 2012-11-30
FR17C1022I1 (ar) 2017-08-09
KR101699707B1 (ko) 2017-01-25
RS55771B1 (sr) 2017-07-31
JP2012511913A (ja) 2012-05-31
RU2015109166A3 (ar) 2018-11-14
RS62580B1 (sr) 2021-12-31
DOP2011000184A (es) 2012-08-15
EP2358756A1 (en) 2011-08-24
PT3156422T (pt) 2021-11-24
US20130085266A1 (en) 2013-04-04
CN102245641B (zh) 2015-01-07
JP5902122B2 (ja) 2016-04-13
KR20110094067A (ko) 2011-08-19
NI201100111A (es) 2011-12-14
UY32329A (es) 2010-07-30
TW201036633A (en) 2010-10-16
PT2358756T (pt) 2017-02-24
CO6571847A2 (es) 2012-11-30
SMT201700183T1 (it) 2017-05-08
US20170096496A1 (en) 2017-04-06
FI2358756T4 (fi) 2023-09-08
ZA201103762B (en) 2012-01-25
IL213050A0 (en) 2011-07-31
HRP20211688T1 (hr) 2022-03-18
US12269897B2 (en) 2025-04-08
US20150284474A1 (en) 2015-10-08
CA2747123A1 (en) 2010-07-08
PA8854201A1 (es) 2010-07-27
KR101504494B1 (ko) 2015-03-20
HRP20170488T1 (hr) 2017-06-02
ES2898661T3 (es) 2022-03-08
AR077724A1 (es) 2011-09-21
PL3156422T3 (pl) 2022-01-31
RU2011129316A (ru) 2013-01-20
US10941210B2 (en) 2021-03-09
RU2697773C2 (ru) 2019-08-20
EP3943510A3 (en) 2022-04-20
IL230771A (en) 2015-05-31
LT3156422T (lt) 2021-11-25
EP3156422A2 (en) 2017-04-19
LTPA2017019I1 (lt) 2017-07-10
TN2011000300A1 (en) 2012-12-17
PL2358756T3 (pl) 2017-06-30
AU2009333326B9 (en) 2015-02-26
EP3943510A2 (en) 2022-01-26
AU2009333326A1 (en) 2010-07-08
LT2358756T (lt) 2017-03-27
US20210253735A1 (en) 2021-08-19
CY2017021I2 (el) 2025-05-09
DK2358756T4 (da) 2023-09-04
AU2009333326B2 (en) 2014-09-11
PE20120014A1 (es) 2012-02-07
MX2011006197A (es) 2011-07-20
ECSP11011134A (es) 2011-07-29
US20250154286A1 (en) 2025-05-15
US20230340153A1 (en) 2023-10-26
US9550837B2 (en) 2017-01-24
SI2358756T1 (sl) 2017-05-31
RU2552169C2 (ru) 2015-06-10
SI3156422T1 (sl) 2022-01-31
WO2010077854A1 (en) 2010-07-08
LUC00024I2 (ar) 2017-09-08
UA105650C2 (uk) 2014-06-10
HUE056244T2 (hu) 2022-02-28
MY203040A (en) 2024-06-05
EP3156422B1 (en) 2021-08-25
CN104447997A (zh) 2015-03-25
NO2017029I1 (no) 2017-06-27
US8062640B2 (en) 2011-11-22
FR17C1022I2 (fr) 2018-07-20
HRP20170488T4 (hr) 2023-09-15
LTC2358756I2 (lt) 2022-04-25
HUS1700029I1 (hu) 2017-07-28
NZ601923A (en) 2013-03-28
JP2013198487A (ja) 2013-10-03
BRPI0922885A2 (pt) 2016-10-04
NO2017029I2 (no) 2017-06-27
US20100166768A1 (en) 2010-07-01
BRPI0922885B1 (pt) 2021-12-21
HN2011001659A (es) 2015-02-02
US8501184B2 (en) 2013-08-06
EP2358756B1 (en) 2017-01-11
US10023654B2 (en) 2018-07-17
MX341041B (es) 2016-08-05
FIC20170031I1 (fi) 2017-07-03
EP3156422A3 (en) 2017-07-05
WO2010077854A8 (en) 2011-07-07
RU2015109166A (ru) 2015-08-10
US20190135941A1 (en) 2019-05-09
DK3156422T3 (da) 2021-11-22
DK2358756T3 (en) 2017-04-10
LUC00024I1 (ar) 2017-07-06
JP5318965B2 (ja) 2013-10-16
CY1118896T1 (el) 2017-11-14
KR20150013359A (ko) 2015-02-04
CY2017021I1 (el) 2017-11-14
US20110065902A1 (en) 2011-03-17
IL213050A (en) 2015-01-29
CN102245641A (zh) 2011-11-16
ES2613489T3 (es) 2017-05-24
RU2552169C3 (ru) 2018-01-19

Similar Documents

Publication Publication Date Title
MY203040A (en) High affinity human antibodies to pcsk9
AU2017204797B2 (en) Antibodies with modified isoelectric points
MX2010004454A (es) Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
AU2014274844A8 (en) Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
MX375117B (es) Proteinas de union a antigeno contra proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
TN2012000243A1 (en) Pcsk9 antagonists
MY157173A (en) Modified humanised anti-interleukin-18
UA114604C2 (uk) Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)
CY1126125T1 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτiλισινης κεξινης τυπου 9 (pcsk9)
MY188372A (en) High affinity human antibodies to pcsk9
TH94437B (th) แอนติบอดี้ของมนุษย์ชนิดที่มีความดึงดูดสูงต่อ pcsk9
TH128000A (th) แอนติบอดี้ของมนุษย์ชนิดที่มีความดึงดูดสูงต่อ pcsk9
Raouf et al. AB0201 Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
LV14471A (lv) Akūta alkohola hepatīta gaitas prognozēšanas paņēmiens
MA37523B1 (fr) Protéines de liaison à l'antigène st2
NZ705644A (en) Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)